Contraindicated in:
Use Cautiously in:
CV: edema, HF, hypertension, MI, vasculitis.
Derm: DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS (DRESS), EXFOLIATIVE DERMATITIS, ↑ sweating, photosensitivity, pruritus, rash, STEVENS-JOHNSON SYNDROME, TOXIC EPIDERMAL NECROLYSIS.
EENT: abnormal vision, tinnitus.
GI: abdominal pain, diarrhea, anorexia, constipation, dry mouth, dyspepsia, flatulence, gastritis, gastroenteritis, GI BLEEDING, ↑ liver enzymes, nausea, stomatitis, vomiting.
GU: albuminuria, azotemia, interstitial nephritis.
Hemat: prolonged bleeding time.
Metab: ↑appetite, weight gain.
Neuro: agitation, anxiety, confusion, depression, dizziness, drowsiness, fatigue, headache, insomnia, malaise, paresthesia, STROKE, tremor, weakness.
Resp: dyspnea, hypersensitivity pneumonitis.
Misc: (INCLUDING ANAPHYLAXIS AND ANGIOEDEMA)HYPERSENSITIVITY REACTIONS .
Drug-Drug:
Relafen, Relafen DS
Absorption: Nabumetone (a prodrug) is 80% absorbed after oral administration; 35% is rapidly converted to 6-methoxy-2-naphthylacetic acid (6-MNA), which is the active drug.
Distribution: Unknown.
Protein Binding: >99%.
Metabolism/Excretion: 6-MNA is metabolized by the liver to inactive compounds.
Half-life: 24 hr (↑ in severe renal impairment).